The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Multiple Sclerosis: Current Knowledge and Future Outlook
Abstract
Background: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system characterized by demyelination and axonal loss. The etiology of MS is unknown; however, environmental and genetic factors play a key role in the development of MS. Diagnostic criteria have been adapted to facilitate earlier diagnosis with increased sensitivity and specificity. Our understanding of the pathophysiology of MS has deepened considerably in recent years, resulting in different therapies to modify the disease course. Furthermore, several drugs have lately shown efficacy in phase III studies and their approval is expected in the near future. As treatment options expand, a future challenge will be to find the optimal treatment for the individual patient. Summary: This mini-review gives an overview of the current knowledge of MS with emphasis on the latest diagnostic criteria and both current and upcoming treatment options. Key Messages: Treatment of MS changes rapidly as the knowledge and therapeutic options in MS expand. Clinical Impact: Diagnosis of MS is based on McDonald criteria. MS therapy can be divided into relapse, disease-modifying and symptomatic treatment. Relapses are commonly treated with intravenous methylprednisolone. First-line therapy consists of either interferon-β, glatiramer acetate or teriflunomide. In general, agents used as escalation therapies (natalizumab, fingolimod and mitoxantrone) are more potent than the agents used for first-line therapy; however, these have potentially serious side effects and should be used with care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
Self-citationDefining the clinical course of multiple sclerosis: Results of an international survey
Lublin, F. D., Reingold, S. C., & National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis* (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,686
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,386
Self-citationNoseworthy, J. H., Lucchinetti, C., Rodriguez, M., & Weinshenker, B. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431307 · Cited by 2,899
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Kappos, L., Radue, E.-W., O'Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Leyk, M., Zhang-Auberson, L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909494 · Cited by 2,644
Self-citationOral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Cohen, J. A., Barkhof, F., Comi, G., Hartung, H.-P., Khatri, B. O., Montalban, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907839 · Cited by 2,204
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Gold, R., Kappos, L., Arnold, D. L., Bar-Or, A., Giovannoni, G., Selmaj, K., Tornatore, C., Sweetser, M. T., Yang, M., Sheikh, S. I., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114287 · Cited by 1,733
Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination
Berer, K., Mues, M., Koutrolos, M., Rasbi, Z. A., Boziki, M., Johner, C., Wekerle, H., & Krishnamoorthy, G. (2011) · Nature · doi:10.1038/nature10554 · Cited by 1,251
Cohen, J. A., Coles, A. J., Arnold, D. L., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., Fisher, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61769-3 · Cited by 1,205
Coles, A. J., Twyman, C. L., Arnold, D. L., Cohen, J. A., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61768-1 · Cited by 1,198
The changing demographic pattern of multiple sclerosis epidemiology
Koch-Henriksen, N., & Sørensen, P. S. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70064-8 · Cited by 1,191
The Immunopathology of Multiple Sclerosis: An Overview
Lassmann, H., Brück, W., & Lucchinetti, C. F. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00064.x · Cited by 1,182
Inflammatory cortical demyelination in early multiple sclerosis.
Lucchinetti, C. F., Popescu, B. F. G., Bunyan, R. F., Moll, N. M., Roemer, S. F., Lassmann, H., Brück, W., Parisi, J. E., Scheithauer, B. W., Giannini, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1100648 · Cited by 1,103
Environmental risk factors for multiple sclerosis. Part I: The role of infection
Ascherio, A., & Munger, K. L. (2007) · Annals of Neurology · doi:10.1002/ana.21117 · Cited by 1,042
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
O'Connor, P., Wolinsky, J. S., Confavreux, C., Comi, G., Kappos, L., Olsson, T. P., Benzerdjeb, H., Truffinet, P., Wang, L., Miller, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014656 · Cited by 990
Hartung, H.-P., Gonsette, R., Konig, N., Kwiecinski, H., Guseo, A., Morrissey, S. P., Krapf, H., & Zwingers, T. (2002) · The Lancet · doi:10.1016/s0140-6736(02)12023-x · Cited by 946
Natural history of multiple sclerosis: a unifying concept
Confavreux, C., & Vukusic, S. (2006) · Brain · doi:10.1093/brain/awl007 · Cited by 905
Temporal trends in the incidence of multiple sclerosis: A systematic review
Alonso, A., & Hernán, M. A. (2008) · Neurology · doi:10.1212/01.wnl.0000316802.35974.34 · Cited by 694
The epidemiology of multiple sclerosis in Europe
Pugliatti, M., Rosati, G., Carton, H., Riise, T., Drulovic, J., Vécsei, L., & Milanov, I. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01342.x · Cited by 654
Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy
Lassmann, H., Brück, W., & Lucchinetti, C. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(00)01909-2 · Cited by 627
Vitamin D and multiple sclerosis
Ascherio, A., Munger, K. L., & Simon, K. C. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70086-7 · Cited by 576
Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis
Marrie, R. A., Rudick, R., Horwitz, R., Cutter, G., Tyry, T., Campagnolo, D., & Vollmer, T. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d6b125 · Cited by 479
Will the real multiple sclerosis please stand up?
Stys, P. K., Zamponi, G. W., van Minnen, J., & Geurts, J. J. G. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3275 · Cited by 475
Timing of birth and risk of multiple sclerosis: population based study
Willer, C. J., Dyment, D. A., Sadovnick, A. D., Rothwell, P. M., Murray, T. J., & Ebers, G. C. (2005) · BMJ · doi:10.1136/bmj.38301.686030.63 · Cited by 451
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring
Kappos, L., Bates, D., Hartung, H.-P., Havrdova, E., Miller, D., Polman, C. H., Ravnborg, M., Hauser, S. L., Rudick, R. A., Weiner, H. L., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70078-9 · Cited by 421
Self-citationPlacebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
Comi, G., Jeffery, D., Kappos, L., Montalban, X., Boyko, A., Rocca, M. A., & Filippi, M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1104318 · Cited by 364
Gold, R., Giovannoni, G., Selmaj, K., Havrdova, E., Montalban, X., Radue, E.-W., Stefoski, D., Robinson, R., Riester, K., Rana, J., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)62190-4 · Cited by 287
The genetics of multiple sclerosis: an up‐to‐date review
Gourraud, P., Harbo, H. F., Hauser, S. L., & Baranzini, S. E. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01134.x · Cited by 282
Parent-of-origin effect in multiple sclerosis: observations in half-siblings
Ebers, G., Sadovnick, A., Dyment, D., Yee, I., Willer, C., & Risch, N. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16304-6 · Cited by 269
Age–adjusted recurrence risks for relatives of patients with multiple sclerosis
Robertson, N. P., Fraser, M., Deans, J., Clayton, D., Walker, N., & Compston, D. A. S. (1996) · Brain · doi:10.1093/brain/119.2.449 · Cited by 234
Incidence and Prevalence of Multiple Sclerosis in the Americas: A Systematic Review
Evans, C., Beland, S.-G., Kulaga, S., Wolfson, C., Kingwell, E., Marriott, J., Koch, M., Makhani, N., Morrow, S., Fisk, J., et al. (2013) · Neuroepidemiology · doi:10.1159/000342779 · Cited by 211
Elian, M., Nightingale, S., & Dean, G. (1990) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.53.10.906 · Cited by 205
Smoking: effects on multiple sclerosis susceptibility and disease progression
Wingerchuk, D. M. (2012) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285611425694 · Cited by 182
Oral versus intravenous steroids for treatment of relapses in multiple sclerosis
Burton, J., O'Connor, P. W., Hohol, M. J., & Beyene, J. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006921.pub3 · Cited by 169
Concordance for multiple sclerosis in Danish twins: an update of a nationwide study
Hansen, T., Skytthe, A., Stenager, E., Petersen, H. C., Brønnum‐Hansen, H., & Kyvik, K. O. (2005) · Multiple Sclerosis Journal · doi:10.1191/1352458505ms1220oa · Cited by 143
Natural history of multiple sclerosis: risk factors and prognostic indicators
Vukusic, S., & Confavreux, C. (2007) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32812583ad · Cited by 137
Biomarkers in Multiple Sclerosis: An Up-to-Date Overview
Katsavos, S., & Anagnostouli, M. C. (2013) · Multiple Sclerosis International · doi:10.1155/2013/340508 · Cited by 129
Torkildsen, N. G., Lie, S. A., Aarseth, J. H., Nyland, H., & Myhr, K.-M. (2008) · Multiple Sclerosis Journal · doi:10.1177/1352458508093890 · Cited by 117
Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice
de, J., Airas, L. M., Bartholome, E. J., Grigoriadis, N., Mattle, H. P., Oreja‐Guevara, C., O’Riordan, J. I., Sellebjerg, F. T., Stankoff, B., Vass, K., et al. (2011) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285611403646 · Cited by 116
Delayed fingolimod-associated asystole
Espinosa, P. S., & Berger, J. R. (2011) · Multiple Sclerosis Journal · doi:10.1177/1352458511410344 · Cited by 75
Neuroprotection in multiple sclerosis: A therapeutic challenge for the next decade
van der Walt, A., Butzkueven, H., Kolbe, S., Marriott, M. P., Alexandrou, E., Gresle, M. M., Egan, G. F., & Kilpatrick, T. J. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.01.006 · Cited by 64
Sudden unexpected death on fingolimod
Lindsey, J. W., Haden‐Pinneri, K., Memon, N., & Buja, L. M. (2012) · Multiple Sclerosis Journal · doi:10.1177/1352458512438456 · Cited by 63
The genetics of multiple sclerosis
Lin, R., Charlesworth, J., van der Mei, I. A. F., & Taylor, B. V. (2012) · Practical Neurology · doi:10.1136/practneurol-2012-000276 · Cited by 62
Interferon Beta and Glatiramer Acetate Therapy
McGraw, C. A., & LUBLIN, F. D. (2012) · Neurotherapeutics · doi:10.1007/s13311-012-0163-4 · Cited by 61
Progressive multifocal leukoencephalopathy in patients with multiple sclerosis
Baldwin, K., & Hogg, J. P. (2013) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328360279f · Cited by 60
Prevalence of Multiple Sclerosis in First Nations People of Alberta
Svenson, L. W., Warren, S., Warren, K. G., Metz, L. M., Patten, S. B., & Schopflocher, D. (2007) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100006004 · Cited by 29
Prevalence of multiple sclerosis in 19 Texas counties, 1998-2000.
Williamson, D., Henry, J. P., Schiffer, R. B., et al. (2007) · PubMed · Cited by 23
Cited by
Sphingolipid metabolism in cancer signalling and therapy
Ogretmen, B. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.96 · Cited by 1,207
Treatment of Multiple Sclerosis: A Review
Hauser, S. L., & Cree, B. A. C. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.05.049 · Cited by 969
Immune responses to stroke: mechanisms, modulation, and therapeutic potential.
Iadecola, C., Buckwalter, M. S., & Anrather, J. (2020) · Journal of Clinical Investigation · doi:10.1172/jci135530 · Cited by 853
B cell depletion therapies in autoimmune disease: advances and mechanistic insights
Lee, D. S. W., Rojas, O. L., & Gommerman, J. L. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00092-2 · Cited by 658
Blood neurofilament light chain as a biomarker of MS disease activity and treatment response
Kuhle, J., Kropshofer, H., Haering, D. A., Kundu, U., Meinert, R., Barro, C., Dahlke, F., Tomic, D., Leppert, D., & Kappos, L. (2019) · Neurology · doi:10.1212/wnl.0000000000007032 · Cited by 568
Metadata
- Authors
- Kamm, C. P., Uitdehaag, B. M., & Polman, C. H.
- Venue
- European Neurology
- Publisher
- S. Karger AG
- Published
- 2014
- Volume
- 72
- Issue
- 3-4
- Pages
- 132-141
- ISSN
- 0014-3022 (ISSN-L)
- 1421-9913
- OpenAlex
- W1986991730
- Cited by
- 1,010
- References
- 49
- FWCI
- 77.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.